- Skin Analytics was founded in 2012 in London, United Kingdom, by CEO and Founder, Neil Daly.
- Skin Analytics uses artificial intelligence to screen for melanoma skin cancer.
- They’re focused on delivering a series of skin health products over the next 3 years ranging from consumer to clinical.
About Skin Analytics
Skin Analytics build a digital history of your skin so that you and your doctor can measure, track and ultimately understand your skin. Meaning you have the tools to take control and ultimately improve your skin health.
Their patent-pending algorithms measure how the skin is changing from smartphone images to identify, inform and evaluate treatment options across a range of consumer health and clinical skin conditions.
Which means they build digital platforms that personalise skin health so people can control their skin health rather than be controlled by it.
Skin Analytics have provided tele-dermatology services for over 5 years and their AI-supported tele-dermatology service since April 2020. The company have spent considerable time working with General Practitioners in Primary Care, Dermatologists, Hospital Providers and leading researchers to ensure that their services and DERM have real clinical utility.
More from MedTech
- How AI is Revolutionising Brain Surgery and Other Medical Practices
- Wearable Health Devices: A Step into the Future
- Dr Owain Rhys Hughes: ‘3 vital lessons I’ve learned as a healthtech founder’
- How MedTech Can Help Tackle The NHS Backlog
- How HealthTech Can Help Relieve Pressure On The NHS And Empower People To Take Control Of Their Own Health
- David Hancock: Why Interoperability In Healthcare Is Vital To Relieving Pressure On The NHS
- Cera Launches Flu Tracker And Treatment System To Protect Older People and The NHS This Winter
- Flow Neuroscience Receives Series A Funding To Make Self-Managed Medical Device Available Globally
Skin Analytics Series A Funding
In September 2020, it was announced that Skin Analytics has raised £4 million in Series A funding. The round was led by Hoxton Ventures, with participation from Nesta and Mustard Seed Ventures.
Skin Analytics says it will use the injection of cash to expand its focus to the U.S. after it was awarded the “Breakthrough Device Designation” by the FDA as part of a programme designed to fast-track new technologies that can have significant impact on the nation’s health.
It also will continue forging partnerships within the U.K.’s national health service, following the launch of what it claims was the world’s first “AI-powered” clinical pathway in conjunction with University Hospital Birmingham.
